Revista Colombiana de psiquiatria
January 1, 2021
Raul Felipe Palma-álvarez, Lara Grau-López, Elena Ros-Cucurull et al.
12 citations
Ayahuasca, a psychotropic infusion made from Amazonian plants, can induce psychotic episodes as a side effect. A patient who experienced such an episode after consuming ayahuasca was successfully treated with antipsychotic medication. The case underscores the need for better understanding and regulation of ayahuasca's social-legal status, further research, and psycho-education to raise awareness of its potential risks.
Therapeutic advances in drug safety
January 1, 2025
Carlos Roncero, Milton Merizalde-Torres, Néstor Szerman et al.
11 citations
Intranasal esketamine, approved in 2019 for treatment-resistant depression, effectively alleviates depressive symptoms with benefits lasting nearly 4.5 years. Long-term clinical studies, case reports, and subsamples of high-risk populations with substance use or alcohol use disorder have not documented abuse, misuse, addiction, or withdrawal. Esketamine is safe and well tolerated without fostering new-onset substance use. Real-world studies report no adverse events from pharmacological interactions and no new-onset drug or alcohol misuse, craving, misuse, or diversion. Only one case report of esketamine craving exists (2022). No illicit acquisition or tampering was found. The review confirms esketamine's safety and the scarcity of abuse or misuse reports.